XKRX003000
Market cap215mUSD
Dec 24, Last price
4,595.00KRW
1D
-1.82%
1Q
-9.01%
Jan 2017
-75.11%
Name
Bukwang Pharm Co Ltd
Chart & Performance
Profile
Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various therapeutic areas, including liver disease treatments, such as Levovir and Legalon; diabetic complication products comprising Dexid and Thioctacid; CNS disorder drugs consisting of Lonasen, Ixel, and Orfil; and respiratory disease treatments, which comprise Azeptin and Asima. It also provides OTC products; toothpastes, and hair and skin care goods; and nutritional supplements. In addition, the company offers products for antihistamines, hepatitis and gastrointestinal, sedative and antidote, anti-cancer, thyroid and osteoporosis, diabetes, obstetrics, urinogenital, cardiovascular, dermatology, obesity, pain relief, and muscle relaxant. Further, it provides products for bruises, skin and mucous membrane, rhinitis, cold symptoms, cough, phlegm and asthma, rheumatoid arthritis, osteoarthritis, pain caused by cold and fever, dysmenorrhea, NSAIDs, inflammation, joint inflammation, tinea pedis, infected wounds, dermatitis, antivirals-herpes, eczema, diarrhea, dyspepsia, sense of distension, anti-histamine, anti-ulcer, constipation, anemia, pregnant multivitamins, candidiasis, athlete's foot, onychomycosis, stomatitis, pimple, acne, physical fatigue, neuralgia, myalgia, and arthralgia. Additionally, the company offers medicines for period of lactation, rickets, night blindness, varicose vein, and sputum; and quasi drugs and medical devices, as well as health functional food. It also develops anti-diabetes compound with Melior Pharmaceuticals; and anti-cancer drugs with LSK BioPartners, as well as cell therapies using adult stem cells, as well as holds a license for a novel candidate to treat movement disorder in Parkinson's disease patients. The company was founded in 1960 and is based in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 125,928,241 -34.04% | 190,909,365 4.61% | 182,491,221 7.56% | |||||||
Cost of revenue | 136,917,436 | 155,577,113 | 142,691,771 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (10,989,195) | 35,332,251 | 39,799,451 | |||||||
NOPBT Margin | 18.51% | 21.81% | ||||||||
Operating Taxes | (5,162,874) | 3,215,805 | 6,584,128 | |||||||
Tax Rate | 9.10% | 16.54% | ||||||||
NOPAT | (5,826,321) | 32,116,447 | 33,215,322 | |||||||
Net income | (31,329,661) 637.40% | (4,248,677) 51.91% | (2,796,798) -72.32% | |||||||
Dividends | (6,845,467) | (6,225,071) | ||||||||
Dividend yield | 1.14% | 0.70% | ||||||||
Proceeds from repurchase of equity | (2,648,797) | (516,193) | ||||||||
BB yield | 0.44% | 0.06% | ||||||||
Debt | ||||||||||
Debt current | 217,604 | 242,909 | 444,171 | |||||||
Long-term debt | 80,031,068 | 1,618,668 | 2,672,564 | |||||||
Deferred revenue | 13,444,933 | 7,578,428 | 6,193,263 | |||||||
Other long-term liabilities | 21,416,135 | 65,201,082 | 61,836,514 | |||||||
Net debt | (102,604,753) | (121,319,882) | (118,003,030) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (10,500,408) | 16,461,450 | 26,524,994 | |||||||
CAPEX | (2,814,665) | (4,990,210) | (789,522) | |||||||
Cash from investing activities | (2,319,128) | (3,151,014) | 4,749,354 | |||||||
Cash from financing activities | 76,838,554 | (10,397,839) | (27,484,627) | |||||||
FCF | 77,160,542 | 43,090,453 | 33,537,260 | |||||||
Balance | ||||||||||
Cash | 151,227,173 | 85,516,748 | 84,277,135 | |||||||
Long term investments | 31,626,252 | 37,664,712 | 36,842,630 | |||||||
Excess cash | 176,557,013 | 113,635,991 | 111,995,204 | |||||||
Stockholders' equity | 270,138,599 | 506,556,705 | 514,711,721 | |||||||
Invested Capital | 145,065,761 | 225,016,827 | 230,106,278 | |||||||
ROIC | 14.11% | 14.19% | ||||||||
ROCE | 10.10% | 11.26% | ||||||||
EV | ||||||||||
Common stock shares outstanding | 68,455 | 68,455 | 68,460 | |||||||
Price | 6,100.00 -30.29% | 8,750.00 -32.17% | 12,900.00 -54.09% | |||||||
Market cap | 417,573,493 -30.29% | 598,978,371 -32.18% | 883,138,373 -54.21% | |||||||
EV | 522,344,475 | 486,288,571 | 775,588,557 | |||||||
EBITDA | (6,696,757) | 40,448,781 | 44,642,207 | |||||||
EV/EBITDA | 12.02 | 17.37 | ||||||||
Interest | 3,807,575 | 1,760,302 | 1,408,313 | |||||||
Interest/NOPBT | 4.98% | 3.54% |